1. Discovery of Triazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys
- Author
-
Chris J. van Koppen, Scott B. Hoyt, Gino Salituro, Elaine Tung, Jim Tata, Joe Clemas, Mark Rosenbach, Jack Gibson, Daphne Szeto, Wei Tang, Andreas Verras, Lee-Yuh Pai, Ning Ren, Carrie Ann Maxwell, Joe Metzger, Jose Castro-Perez, Qing Chen, Lina Yin, Daniel R. McMasters, Yusheng Xiong, Rolf W. Hartmann, Mary Struthers, Gui-Bai Liang, Charlene Bopp, Xiuying Ma, Gaochao Zhou, Richard Hajdu, Tom Wisniewski, Mike E. Lassman, Nicole Buist, Clare London, Andrea Sok, Gail Forrest, Sloan Stribling, Theresa McLaughlin, Qingzhong Hu, Tian-Quan Cai, and Whitney Lane Petrilli
- Subjects
Aldosterone synthase ,medicine.medical_specialty ,Aldosterone ,Organic Chemistry ,Triazole ,Hit to lead ,Biology ,Pharmacology ,Biochemistry ,chemistry.chemical_compound ,Endocrinology ,chemistry ,Pharmacokinetics ,In vivo ,Pharmacodynamics ,Internal medicine ,Drug Discovery ,medicine ,biology.protein ,Cortisol level - Abstract
Hit-to-lead efforts resulted in the discovery of compound 19, a potent CYP11B2 inhibitor that displays high selectivity vs related CYPs, good pharmacokinetic properties in rat and rhesus, and lead-like physical properties. In a rhesus pharmacodynamic model, compound 19 displays robust, dose-dependent aldosterone lowering efficacy, with no apparent effect on cortisol levels.
- Published
- 2015